West Pharmaceutical Services, Inc. (NYSE:WST) was upgraded by research analysts at Jefferies Group LLC from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday. The firm presently has a $115.00 price target on the medical instruments supplier’s stock, up from their prior price target of $96.00. Jefferies Group LLC’s price target indicates a potential upside of 19.90% from the company’s previous close. Jefferies Group also issued estimates for West Pharmaceutical Services’ Q2 2018 earnings at $0.81 EPS.
A number of other brokerages also recently issued reports on WST. Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $114.00 price objective for the company in a research report on Friday, June 9th. BidaskClub downgraded West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $98.52.
Shares of West Pharmaceutical Services (WST) opened at 95.91 on Friday. West Pharmaceutical Services has a 1-year low of $70.17 and a 1-year high of $99.91. The stock has a market capitalization of $7.10 billion, a price-to-earnings ratio of 41.16 and a beta of 1.13. The company has a 50-day moving average of $87.41 and a 200-day moving average of $89.29.
West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. The firm had revenue of $397.60 million during the quarter, compared to the consensus estimate of $406.00 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The company’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period last year, the company earned $0.59 EPS. On average, equities research analysts expect that West Pharmaceutical Services will post $2.68 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/09/17/west-pharmaceutical-services-inc-wst-rating-increased-to-buy-at-jefferies-group-llc.html.
Institutional investors have recently made changes to their positions in the stock. Acrospire Investment Management LLC purchased a new position in West Pharmaceutical Services during the 2nd quarter valued at about $113,000. Citigroup Inc. boosted its holdings in West Pharmaceutical Services by 95.1% during the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 765 shares during the period. Wolverine Trading LLC purchased a new position in West Pharmaceutical Services during the 2nd quarter valued at about $200,000. Nomura Holdings Inc. purchased a new position in West Pharmaceutical Services during the 2nd quarter valued at about $201,000. Finally, Bradley Foster & Sargent Inc. CT purchased a new position in West Pharmaceutical Services during the 2nd quarter valued at about $212,000. Institutional investors own 91.25% of the company’s stock.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.